Improving Transplant Med Safety through a Pharmacist-Led, mHealth-Based Program

通过药剂师主导、基于移动医疗的计划提高移植医疗安全

• 批准号: 9361634
• 负责人: David J. Taber
• 金额: $ 50万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-01 至 2020-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9361634
• 关键词: Improving; Transplant; Med; Safety; through

PROJECT SUMMARY Although the contemporary use of immunosuppression regimens have dramatically reduced the incidence of acute rejection, long-term graft survival continues to be suboptimal in kidney transplantation. Studies suggest that adverse drug events and medication errors, both of which encompass medication safety issues, may be a predominant cause of graft loss. However, despite kidney transplant recipients being at high-risk for medication safety events, there is limited information surrounding the incidence, etiologies and outcomes of medication errors and adverse drug events within this population. Our preliminary research has demonstrated that significant medication errors, predominantly due to patient-related factors, occur in nearly two-thirds of kidney transplant recipients, leading to hospitalization in one out of every eight patients. Recipients that develop clinically significant medication errors are at considerably higher risk of deleterious clinical outcomes, most significantly graft loss; these patients also develop substantially more adverse drug events, readmissions and acute rejections. Researchers have also demonstrated feasibility and high acceptability of mobile health (mHealth) technology use to bridge communication gaps that often lead to medication safety issues. Smartphone and home-based monitoring technology has a very high penetration rate within this population. These studies establish that a pharmacist-empowered, patient-centered, mHealth-based intervention provides an innovative and highly promising opportunity to improve medication safety in kidney transplantation. It is within this context that the investigators propose to conduct the Improving Transplant Medication Safety through a Pharmacist-Empowered, Patient-Centered, mHealth-Based Intervention (TRANSAFE Rx) study. The primary goal of the TRANSAFE Rx study is to demonstrate significant reductions in medication safety issues leading to reduced healthcare resource utilization in kidney transplantation through a pharmacist-led, mHealth-enabled, intervention. Conducting this study will provide detailed and novel information on the incidence, etiologies and outcomes of medication errors and adverse drug events in this high-risk population; while also demonstrating the effectiveness of this intervention on reducing the incidence and impact of medication safety issues in kidney transplantation. The enduring goals of this study are to demonstrate a highly effective, efficient and deployable method to improve medication safety in high risk patient populations with the long-term objective of disseminating this promising technology and intervention across multiple patient types and healthcare environments.

项目总结 尽管现代免疫抑制疗法的使用大大降低了 在肾移植中，急性排斥反应、移植物的长期存活率仍然是次优的。研究表明 药品不良事件和用药差错，两者都涉及用药安全问题，可能是 移植物丢失的主要原因。然而，尽管肾移植接受者有很高的风险 药物安全事件，关于以下疾病的发生率、病因和结果的信息有限 这一人群中的用药差错和不良药物事件。我们的初步研究表明 重大用药差错，主要是由于与患者有关的因素，发生在近三分之二 肾移植受者，导致每八名患者中就有一名患者住院。收件人 出现临床上的重大用药差错具有相当高的有害临床结果的风险， 最显著的移植物丢失；这些患者还会发生更多的不良药物事件，再次住院 和急性排斥反应。研究人员还证明了移动医疗的可行性和高可接受性 (MHealth)技术用于弥合经常导致药物安全问题的沟通差距。 智能手机和家庭监控技术在这一人群中的普及率非常高。 这些研究表明，由药剂师授权、以患者为中心、以移动健康为基础的干预措施提供了 这是一个提高肾移植用药安全性的创新和极具前景的机会。它是 在此背景下，调查人员建议进行提高移植用药安全性 通过一项由药剂师授权、以患者为中心、以mHealth为基础的干预(TRANSAFE Rx)研究。 TRANSAFE Rx研究的主要目标是证明药物安全性显著降低 通过药剂师领导的，导致肾移植中医疗资源利用率降低的问题， 启用移动健康，进行干预。进行这项研究将提供详细和新颖的信息 在这一高危人群中，用药差错和不良药物事件的发生率、病因和结局； 同时也证明了这一干预措施在减少肺炎发病率和影响方面的有效性 肾移植中的用药安全问题。这项研究的持久目标是证明 高效、高效和可部署的方法，提高高危患者人群的用药安全性 长期目标是在多名患者中传播这项前景光明的技术和干预措施 类型和医疗保健环境。